Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00543569 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
A Phase 2 study of Kidney Transplantation, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 323
- Enrollment target
- 20
- Study locations
NCT00543569 is a Phase 2 study of Kidney Transplantation that has completed, run by Astellas Pharma. The registered enrollment target is 323 participants, above the 258-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (25% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT00543569, a Phase 2 study of Kidney Transplantation, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 323 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study to assess the safety and efficacy of Alefacept in de novo kidney transplant patients.
Conditions Studied
Interventions
- DRUG Corticosteroids
- DRUG tacrolimus
- DRUG mycophenolate mofetil
- DRUG basiliximab
- DRUG Alefacept
Study Locations (20)
California
- Loma Linda University Medical Center - Loma Linda
- University of Southern California - University Hospital - Los Angeles
- St. Vincent/National Institute of Transplantation - Los Angeles
- UC Davis Medical Center - Sacramento
- UCSD - San Diego
- California Institute of Renal Research/Sharp Memorial Hospital - San Diego
- University of California - San Francisco - San Francisco
Illinois
- Rush - Presbyterian - St. Lukes Medical Center - Chicago
- University of Illinois at Chicago - Chicago
- University of Chicago Medical Center - Chicago
Florida
- University of Florida, Shands Hospital, Gainesville - Gainesville
- Mayo Clinic - Jacksonville - Jacksonville
Massachusetts
- Tufts Medical Center - Boston
- Brigham and Women's Hospital - Boston
Colorado
- University of Colorado Health Science Center - Aurora
Georgia
- Medical College of Georgia, Augusta - Augusta
Kentucky
- University of Kentucky - Lexington
Maryland
- University of Maryland Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 323 participants |
| Start Date | 2008-02 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00543569
The ClinicalTrials.gov registry entry for NCT00543569 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 323 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 258-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (25% higher). The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Transplantation appearing as the primary indexed condition, and to 5 interventions - of which Corticosteroids is the first listed.
NCT00543569 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT00543569 about?
NCT00543569 is a clinical study titled "A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients". A study to assess the safety and efficacy of Alefacept in de novo kidney transplant patients.
What is the current status of trial NCT00543569?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 323 participants. The study started on 2008-02. Estimated completion is 2011-02.
What conditions does trial NCT00543569 study?
This clinical trial studies the following conditions: Kidney Transplantation.
What interventions are being tested in trial NCT00543569?
The interventions under investigation include: Corticosteroids (DRUG), tacrolimus (DRUG), mycophenolate mofetil (DRUG), basiliximab (DRUG), Alefacept (DRUG).
Who is sponsoring clinical trial NCT00543569?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00543569 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
REgulatory T Cell Therapy to Achieve Immunosuppression REduction
RECRUITING · Phase 2
-
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
RECRUITING · Phase 2
-
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)
ACTIVE NOT RECRUITING · Phase 2
-
The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
COMPLETED · Phase 2
-
Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.